Lupin Pharmaceuticals Defends Against False Labeling Litigation

Defended Lupin Pharmaceuticals against claims of false and defective labeling and advertising related to one of its drug products. The case centered on the federal preemption defense and the Hatch-Waxman Act applicable to generic pharmaceuticals.*

*prior firm experience